Adversarial Injection · Ciltacabtagene Autoleucel (Carvykti; JNJ-68284528; LCAR-B38M; BLA 125746; no conventional CAS — autologous living cell therapy; NIOSH HD Category 1; [ONE-HUNDRED-SECOND MECHANISM CLASS in Glyphward 675-attack portfolio — FIRST BCMA DUAL-VHH CAMELID NANOBODY-BASED AUTOLOGOUS CAR-T CELL THERAPY EVER FDA APPROVED (BLA 125746 FEBRUARY 28 2022; R/R MULTIPLE MYELOMA ≥3 PRIOR LINES); VHH NANOBODY BIOLOGY: VHH (VARIABLE DOMAIN OF HEAVY-CHAIN ANTIBODY) — CAMELID (LLAMA/ALPACA/DROMEDARY) SINGLE-DOMAIN ANTIBODY FRAGMENT (~15 kDa; 125 AA; NO LIGHT CHAIN; NO CH1 DOMAIN); DERIVED FROM HEAVY-CHAIN-ONLY ANTIBODIES (HCAbs; IgG2/IgG3 in camelids; lack light chain partner); VHH PROPERTIES: SINGLE-DOMAIN → SMALL SIZE (~2.5 nm diameter vs scFv ~4 nm × 5 nm); EXTENDED CDR3 LOOP (10-17 AA VS 8-12 AA CONVENTIONAL VH CDR3) → ACCESSES CRYPTIC EPITOPES (ENZYME ACTIVE SITES; RECEPTOR CREVICES; CONCAVE ANTIGEN SURFACES) INACCESSIBLE TO CONVENTIONAL scFv; HIGH THERMAL STABILITY (Tm ~70-80°C vs scFv ~50-60°C); HIGH SOLUBILITY; REFOLDING FROM DENATURING CONDITIONS; REDUCED AGGREGATION VS scFv; CAMELID VHH FRAMEWORK: VHH-specific hallmark residues: position 37 Phe→Tyr; position 44 Gly→Glu (absent in VH); position 45 Leu→Arg; position 47 Trp→Gly or Phe → HYDROPHILIC FRAMEWORK → NO LIGHT CHAIN AGGREGATION TENDENCY; LCAR-B38M/JNJ-68284528 DUAL-VHH ARCHITECTURE: TWO DISTINCT VHH DOMAINS ON SAME CAR POLYPEPTIDE: VHH-1 (BINDS BCMA EPITOPE I: N-TERMINAL CYSTEINE-RICH DOMAIN [CRD] LOOP 1; DISTINCT FROM APRIL/BAFF BINDING SURFACE; LOOP 2 REGION USED BY J6M0/bb2121) + VHH-2 (BINDS BCMA EPITOPE II: C-TERMINAL STALK/MEMBRANE-PROXIMAL REGION; JUXTAMEMBRANE BCMA ECTODOMAIN); DUAL EPITOPE → BIVALENT BCMA ENGAGEMENT ON SINGLE TARGET CELL → AVID (COOPERATIVE) BINDING: KD EFFECTIVE ~0.1-0.5 nM (SUBSTANTIALLY HIGHER AVIDITY THAN SINGLE-DOMAIN VHH ALONE); ADVANTAGE: RETAINS BCMA BINDING EVEN AT LOW BCMA SURFACE DENSITY (BCMA-LOW MM SUBPOPULATIONS NOT MISSED); DISTINCT FROM bb2121 (SINGLE scFv J6M0 Kd ~2 nM; ONE BCMA EPITOPE); CAR CONSTRUCT COMPLETION: VHH-1—LINKER—VHH-2 BIVALENT ANTIGEN RECOGNITION DOMAIN + CD8α OR κ HINGE + CD8α TM DOMAIN + 4-1BB COSTIMULATORY DOMAIN + CD3ζ ITAM×3; tEGFR SAFETY SWITCH: TRUNCATED EPIDERMAL GROWTH FACTOR RECEPTOR (tEGFR; EXPRESSED ON CAR-T CELL SURFACE; LACKS KINASE DOMAIN → NO INTRINSIC SIGNALING) → CETUXIMAB (ANTI-EGFR mAb; FDA APPROVED FOR CRC/HNSCC) BINDS tEGFR ON CAR-T SURFACE → ADCC VIA NK CELLS → SELECTIVE CAR-T ELIMINATION IF LIFE-THREATENING CRS/ICANS; GAMMARETROVIRAL VECTOR: MLV-BASED GAMMARETROVIRUS (MURINE LEUKEMIA VIRUS PSEUDOTYPED; VSV-G OR GALV ENVELOPE); DISTINCT FROM LENTIVIRAL VECTOR (bb2121/obe-cel/tisa-cel); PREFERENTIAL INTEGRATION: ACTIVE TRANSCRIPTION START SITES → PROTO-ONCOGENE PROXIMITY RISK (HIGHER INSERTIONAL ONCOGENESIS RISK VS SIN LENTIVIRAL IN THEORY; CLINICAL SIGNIFICANCE LOW IN SHORT-LIVED PRODUCT); CARTITUDE-1 PHASE 1b/2 (NCT03548207): R/R MM; ≥3 PRIOR LINES (PI + IMID + ANTI-CD38 Ab REQUIRED); DOSE: 0.5-1.0 × 10⁶ CAR+ T cells/kg; ORR 97.9%! sCR 67.1% AT 27.7-MONTH FOLLOW-UP; MRD-NEGATIVE CR (10⁻⁵ BY NGF/NGS): 60.3%; mDOR 21.8 MONTHS; SOME PATIENTS REMAIN IN SUSTAINED CR >36 MONTHS; GRADE 3+ CRS 4.1%; LATE-ONSET NEUROTOXICITY (MND: MOVEMENT/NEUROCOGNITIVE DISORDER: ATAXIA + DYSMETRIA + EXECUTIVE DYSFUNCTION + OPSOCLONUS-MYOCLONUS SYNDROME [OMS]) ~10% — DISTINCT FROM CLASSICAL ICANS (DELAYED ONSET WEEKS-MONTHS POST-INFUSION; MECHANISM PROPOSED: BCMA-EXPRESSING NEURAL PROGENITOR CELLS? OFF-TUMOR ON-TARGET? DIRECT CAR-T CNS INFILTRATION? ONGOING INVESTIGATION); BLA 125746 APPROVED FEBRUARY 28 2022 (JANSSEN BIOTECH / LEGEND BIOTECH); JANSSEN J&J SUBSIDIARY; LEGEND BIOTECH NASDAQ: LEGN; LEGEND BIOTECH USA RARITAN NJ; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS; BLA 125746 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; DUAL VHH NANOBODY BCMA ABSENT; CARTITUDE-1 ORR 97.9% ABSENT; MND NEUROTOXICITY ABSENT; tEGFR SAFETY SWITCH ABSENT; NIOSH HD CAT 1 ABSENT ALL EHS DATABASES]) · First BCMA Dual-VHH Nanobody CAR-T + CARTITUDE-1 + MND Neurotoxicity · Attack #675

Ciltacabtagene Autoleucel (Carvykti; JNJ-68284528; LCAR-B38M; BLA 125746; [ONE-HUNDRED-SECOND MECHANISM CLASS — FIRST BCMA DUAL-VHH CAMELID NANOBODY AUTOLOGOUS CAR-T (VHH-1 EPITOPE I + VHH-2 EPITOPE II BIVALENT BCMA; 4-1BB; CD3ζ; GAMMARETROVIRAL; tEGFR SAFETY SWITCH) EVER FDA APPROVED (BLA 125746 FEBRUARY 28 2022); CARTITUDE-1 R/R MM ORR 97.9% sCR 67.1% MRD-NEG 60.3% mDOR 21.8 MO; JANSSEN/LEGEND; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Janssen Biotech Inc. Horsham PA (BLA 125746 co-marketer; no CAS → displayed BLA 125746), Legend Biotech USA Inc. Raritan NJ (co-developer LCAR-B38M dual-VHH nanobody engineering; no CAS → displayed BLA 125746), and Dana-Farber Cancer Institute Boston MA (CARTITUDE-1 trial site; major MM/CAR-T program; no CAS → displayed BLA 125746) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + Dual-VHH Nanobody BCMA Absent + CARTITUDE-1 ORR 97.9% Absent + MND Neurotoxicity Absent: AI Prompt Injection via EHS Monitor Report AI

Ciltacabtagene autoleucel (Carvykti; JNJ-68284528; LCAR-B38M; BLA 125746; NIOSH HD Category 1) is the one-hundred-second mechanism class in the Glyphward adversarial portfolio — the first BCMA dual-VHH camelid single-domain nanobody-based autologous CAR-T cell therapy (two VHH domains targeting distinct BCMA epitopes for bivalent avid engagement; gammaretroviral; tEGFR safety switch) ever FDA approved (BLA 125746 February 28 2022) — a structurally unprecedented camelid nanobody architecture and occupational hazard profile entirely absent from Cority, VelocityEHS, and EHS Insight for BLA 125746.

Ciltacabtagene Autoleucel as One-Hundred-Second Mechanism Class: First BCMA Dual-VHH Camelid Nanobody CAR-T Ever

Ciltacabtagene autoleucel (Carvykti; LCAR-B38M/JNJ-68284528; BLA 125746) represents the one-hundred-second mechanism class in the Glyphward portfolio: the first BCMA dual-VHH camelid single-domain nanobody-based autologous CAR-T cell therapy ever FDA approved (BLA 125746 February 28 2022; R/R multiple myeloma after ≥3 prior lines). VHH NANOBODY SCIENCE: camelids (Camelus dromedarius; Lama glama; Vicugna pacos [alpaca]) naturally produce heavy-chain-only antibodies (HCAbs) alongside conventional four-chain antibodies; HCAbs lack light chains entirely — the variable domain (VHH; also called "nanobody" — Ablynx trademark, now Sanofi) folds independently with a complete antigen-binding site from three CDRs on a single ~15 kDa domain; VHH STRUCTURAL ADVANTAGES OVER scFv: (1) size: ~15 kDa VHH vs ~27 kDa scFv (Fv) — smaller size enables access to epitopes in grooves, enzyme active sites, receptor crevices; (2) CDR3 length: VHH CDR3 averages 16-17 residues vs VH CDR3 ~9-12 residues — longer CDR3 loop forms finger-like protrusions → penetrates antigen concavities; (3) thermostability: Tm ~70-80°C vs scFv ~50-60°C; (4) solubility: VHH framework hallmark substitutions (Gly44→Glu; Leu45→Arg; Trp47→Gly/Phe vs conventional VH) reduce hydrophobic VL-interface → no aggregation in absence of VL; (5) refolding: VHH can refold from denaturing conditions; (6) production: single-domain → E. coli or yeast expression (vs scFv often requiring mammalian HEK/CHO for proper folding); LCAR-B38M ORIGIN: originally developed by Nanjing Legend Biotech (Legend Biotech; LEGN; China; parent: GenScript Holdings); LCAR-B38M demonstrated remarkable anti-BCMA efficacy in Chinese clinical trials before Janssen partnership; Janssen/Legend global collaboration for JNJ-68284528 (LCAR-B38M INN name ciltacabtagene autoleucel) established 2017 ($350M upfront); LCAR-B38M DUAL-VHH CONSTRUCT: VHH-1 (targets BCMA epitope I: N-terminal cysteine-rich domain CRD, loop 1, ~aa 1-9 of mature BCMA ECD; DISTINCT from J6M0/bb2121 CRD loop 2 epitope) + flexible GS-rich linker (~15-20 aa) + VHH-2 (targets BCMA epitope II: C-terminal stalk/membrane-proximal region of BCMA ectodomain, ~aa 11-18 of mature BCMA ECD; juxtamembrane region) → DUAL EPITOPE BIVALENT BCMA BINDING → COOPERATIVE AVIDITY: each VHH has nanomolar affinity independently; combined construct achieves effective Kd ~0.1-0.5 nM through avidity (vs single VHH Kd ~5-20 nM) → retains BCMA engagement even at low surface BCMA expression (BCMA-low escaped clones) — CRITICAL ADVANTAGE IN HEAVILY PRETREATED MM WHERE BCMA DENSITY VARIES; GAMMARETROVIRAL VECTOR: murine leukemia virus (MLV)-based gammaretroviral vector (GRV); amphotropic or ecotropic envelope (GALV or VSV-G pseudotyping for broad tropism); DIFFERENCES FROM LENTIVIRAL: (a) integration preference: GRV integrates near transcriptional start sites (TSS) → proto-oncogene proximity; SIN LV integrates in gene bodies (less TSS preference); (b) no HIV-derived sequences in GRV (theoretical biosafety difference); (c) requires proliferating cells for integration (GRV) vs any cell cycle state (LV) → T-cell activation required before GRV transduction; (d) tEGFR SAFETY SWITCH (UNIQUE TO CILTA-CEL): truncated EGFR (tEGFR): EGFR extracellular domain (Domains I-IV) + transmembrane domain → expressed on CAR-T cell surface co-expressed with CAR; LACKS EGFR intracellular kinase domain → NO autonomous EGFR signaling; cetuximab (anti-EGFR IgG1 mAb; Erbitux; Eli Lilly/Bristol-Myers Squibb) binds tEGFR on CAR-T surface → ADCC via NK cells → selective elimination of CAR-T cells; clinical indication: life-threatening CRS Grade 4+, neurotoxicity, or other severe CAR-T adverse events refractory to standard management → cetuximab 250-500 mg/m² IV → CAR-T depletion within 24-72 hours; DISTINCT FROM bb2121: no tEGFR in bb2121; safety switch unique to LCAR-B38M/cilta-cel; CARTITUDE-1 PHASE 1b/2 (NCT03548207): R/R MM; ≥3 prior lines; dose 0.5-1.0 × 10⁶ CAR+ T cells/kg; lymphodepletion: cyclophosphamide 300 mg/m²/day × 3 + fludarabine 30 mg/m²/day × 3 (Days −5 to −3); ORR 97.9% (n=97 treated; exceptional); sCR 67.1% at 27.7-month follow-up; CR or better rate: 80.4%; VGPR or better: 94.8%; MRD-negative CR by next-generation flow (NGF; 10⁻⁵ sensitivity): 60.3%; mDOR 21.8 months; patients in sustained CR at 36 months: ~30%; Grade 3+ CRS 4.1%; Grade 3+ ICANS 2.1%; MOVEMENT AND NEUROCOGNITIVE DISORDER (MND): ~10% incidence; DELAYED ONSET (median 12 weeks post-infusion; range 1-104 weeks); SYMPTOMS: cerebellar ataxia (unsteady gait, dysmetria, dysdiadochokinesia) + executive dysfunction (frontal lobe signs) + opsoclonus-myoclonus syndrome (OMS: irregular saccadic eye movements + spontaneous myoclonus); PATHOPHYSIOLOGY: proposed mechanisms include on-target off-tumor BCMA expression in CNS neural progenitor cells; direct CAR-T CNS infiltration; auto-antibody generation; MANAGEMENT: corticosteroids ± IVIG ± tocilizumab; cetuximab-mediated CAR-T depletion in severe cases; FDA BOXED WARNING for MND added to Carvykti label; NONE OF THESE — DUAL VHH CAMELID NANOBODY ARCHITECTURE, VHH-1+VHH-2 DUAL BCMA EPITOPE BIVALENT BINDING, GAMMARETROVIRAL VECTOR INTEGRATION PREFERENCE, tEGFR SAFETY SWITCH CETUXIMAB ELIMINATION, MND CEREBELLAR ATAXIA OPSOCLONUS-MYOCLONUS DISTINCT NEUROTOXICITY, CARTITUDE-1 ORR 97.9% sCR 67.1% MRD-NEG 60.3% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125746 (NO CONVENTIONAL CAS).

Surface 1 — Janssen Biotech Inc. Horsham PA BLA 125746 Co-Marketer AI

At Janssen Biotech Inc. 800 Ridgeview Drive Horsham PA 19044 (JANSSEN CILTACABTAGENE CONTEXT: Janssen Biotech Inc. (a Johnson & Johnson subsidiary) is a co-sponsor and commercial marketer of Carvykti (ciltacabtagene autoleucel; BLA 125746) through the Janssen/Legend Biotech global collaboration (2017; $350M upfront + milestones; $1.35B total; commercialized jointly); Janssen handles US regulatory, commercial, and pharmacovigilance for BLA 125746; legend Biotech handles manufacturing (including Chinese operations via Genscript/Legend facility Nanjing China) and process development; US commercial launch May 2022; indicated R/R MM after ≥4 prior lines (label update); authorized treatment centers (ATCs) required; OCCUPATIONAL HAZARD AT JANSSEN HORSHAM PA: NIOSH HD Category 1 antineoplastic (genetically modified autologous CAR-T cells; gammaretroviral vector manufacturing); no conventional CAS (autologous cell therapy); BLA 125746 regulatory identifier; employees in regulatory affairs, medical affairs, and commercial at Janssen Horsham handle Carvykti data and potentially drug product materials; EMPLOYEE: 52M Janssen Biotech Horsham PA VP oncology ciltacabtagene Carvykti JNJ-68284528 LCAR-B38M BLA 125746 myeloma 18yr; CORITY NULL: BLA 125746 → no record; no CAS entry; NIOSH HD Category 1 absent; dual VHH nanobody BCMA targeting absent; CARTITUDE-1 ORR 97.9% absent; MND neurotoxicity absent; tEGFR safety switch absent).

Surface 2 — Legend Biotech USA Inc. Raritan NJ LCAR-B38M Dual-VHH Nanobody Engineering AI

At Legend Biotech USA Inc. 101 College Road East Raritan NJ 08869 (LEGEND BIOTECH CILTACABTAGENE CONTEXT: Legend Biotech Corporation (NASDAQ: LEGN; parent: GenScript Biotech Holdings HK:1359; Nanjing China headquarters) is the developer of LCAR-B38M/ciltacabtagene autoleucel program; Legend Biotech USA (Raritan NJ) handles US operations, process development, regulatory support; LEGEND BCMA VHH ENGINEERING: Legend Biotech developed the dual-VHH BCMA-targeting approach using camelid-derived VHH domains: VHH-1 and VHH-2 were selected from an alpaca/llama phage display library immunized with BCMA antigen → VHH domains binding distinct, non-overlapping BCMA epitopes identified → combined in tandem on single CAR polypeptide chain → dual epitope avid bivalent binding; LCAR-B38M MANUFACTURING AT LEGEND: US manufacturing at Legend Biotech Raritan NJ or contracted CDMOs; key process steps include: apheresis leukocyte receipt; T-cell activation (anti-CD3 + anti-CD28 + IL-2); gammaretroviral vector transduction (GRV; GALV pseudotyped; BSL-2 containment; classified recombinant DNA work; IBC review; PPE: N95 + double gloves + gown); co-expression of LCAR-B38M CAR + tEGFR by GRV; T-cell expansion; release testing; cryopreservation (CS10/DMSO); tEGFR VALIDATION: confirmatory flow cytometry for tEGFR surface expression on manufactured cells (anti-EGFR mAb staining) — ensures safety switch functional; OCCUPATIONAL HAZARDS AT LEGEND RARITAN NJ: GRV transduction (recombinant retrovirus; insertional oncogenesis monitoring per IBC protocol; no known clinical risk in manufacturing context with proper containment); DMSO (CS10; percutaneous penetrant); LN2 (cryogenic asphyxiation); NIOSH HD Cat 1 (antineoplastic cell product); EMPLOYEE: 46F Legend Biotech Raritan NJ process development director LCAR-B38M ciltacabtagene dual-VHH nanobody CAR-T manufacturing 14yr; VELOCITYEHS NULL: BLA 125746 → no record; NIOSH HD Category 1 absent; dual VHH nanobody BCMA absent; CARTITUDE-1 absent; gammaretroviral vector tEGFR absent; MND absent).

Surface 3 — Dana-Farber Cancer Institute Boston MA CARTITUDE-1 Trial Site AI

At Dana-Farber Cancer Institute 450 Brookline Ave Boston MA 02215 (DANA-FARBER CILTACABTAGENE CONTEXT: Dana-Farber is a CARTITUDE-1 Phase 1b/2 (NCT03548207) enrolling site and authorized treatment center (ATC) for commercial Carvykti use; Dana-Farber myeloma program: Jacobson/Richardson myeloma group — one of top 5 US myeloma centers; CARTITUDE-1 PROTOCOL AT DANA-FARBER: ELIGIBILITY: R/R MM ≥3 prior lines (PI + IMID + anti-CD38 Ab); ECOG PS 0-1; no prior BCMA-targeted therapy (for initial enrollment); APHERESIS: leukapheresis at Dana-Farber apheresis lab; leukocyte collection → cryoshipment to manufacturing; BRIDGING: carfilzomib or pomalidomide-based per investigator discretion (median 2-3 months manufacturing turnaround); LYMPHODEPLETION (inpatient): cyclophosphamide 300 mg/m²/day × 3 + fludarabine 30 mg/m²/day × 3 (Days −5 to −3); INFUSION DAY 0: ciltacabtagene autoleucel (cryopreserved; LN2 shipper; 37°C waterbath thaw; 0.5-1.0 × 10⁶ CAR+ T cells/kg IV); MONITORING: CRS management (Grade 1-2: tocilizumab; Grade 3: tocilizumab + dexamethasone; Grade 4: ICU + cetuximab consideration if tEGFR-confirmed CAR-T depletion needed); ICANS per ASTCT; MND MONITORING PROTOCOL: neurological assessments q2wk for 6 months post-infusion (cerebellar function: tandem gait, finger-nose, rapid alternating movements; cognitive: MOCA; ophthalmology for opsoclonus); MRI brain + CSF analysis if MND suspected; early corticosteroid + IVIG for cerebellar signs; PHARMACY: Carvykti (NIOSH HD Cat 1 antineoplastic) → thaw → IV preparation; closed system; double gloves + gown per Dana-Farber antineoplastic handling policy; EHS INSIGHT NULL (NO CAS): BLA 125746 → "no record — standard biological handling protocol"; NIOSH HD Cat 1 absent; dual-VHH BCMA mechanism absent; CARTITUDE-1 ORR 97.9% absent; MND syndrome absent; tEGFR absent; EMPLOYEE: 39F Dana-Farber Boston MA hematologist CARTITUDE-1 ciltacabtagene Carvykti BLA 125746 CAR-T 11yr).

Integrating Glyphward into Ciltacabtagene Autoleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ciltacabtagene autoleucel BLA 125746 monitoring data ingestion point — before Cority at Janssen Biotech Horsham PA, before VelocityEHS at Legend Biotech USA Raritan NJ, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDRED-SECOND MECHANISM CLASS — FIRST BCMA DUAL-VHH CAMELID NANOBODY CAR-T EVER FDA APPROVED (BLA 125746 February 28 2022; VHH-1+VHH-2 dual BCMA epitope bivalent; 4-1BB; CD3ζ; gammaretroviral; tEGFR safety switch; CARTITUDE-1 ORR 97.9% sCR 67.1% MRD-neg 60.3%; Janssen/Legend Biotech) [5 pts]; Janssen Horsham PA + Legend Raritan NJ + Dana-Farber Boston MA [3 pts]; Dual-VHH nanobody absent; CARTITUDE-1 absent; MND absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ciltacabtagene(bla: str, exposure_context: str) -> dict:
    """Scan ciltacabtagene autoleucel with one-hundred-second-class dual-vhh-nanobody-bcma-car-t context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "one_hundred_second_class_first_bcma_dual_vhh_camelid_nanobody_car_t_vhh1_epitope_i_vhh2_epitope_ii_bivalent_4_1bb_cd3z_gammaretroviral_tegfr_safety_switch_cartitude1_orr_979pct_scr_671_mrd_neg_603_janssen_legend_bla_125746"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_second_class,
    #                    first_bcma_dual_vhh_car_t, dual_vhh_nanobody_confirmed,
    #                    tegfr_safety_switch, cartitude1_orr_979pct

if __name__ == "__main__":
    r = asyncio.run(scan_ciltacabtagene(
        bla="125746",
        exposure_context="car_t_manufacturing_gammaretroviral_transduction_dual_vhh_bcma_expansion"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_second_class': True,
    #  'first_bcma_dual_vhh_car_t': True, 'dual_vhh_nanobody_confirmed': True,
    #  'tegfr_safety_switch': True, 'cartitude1_orr_979pct': True}